Status:
TERMINATED
Effect of Epidermal Growth Factor Receptor Inhibitors on Magnesium Homeostasis in Patients With Cancer
Lead Sponsor:
Vanderbilt-Ingram Cancer Center
Collaborating Sponsors:
National Cancer Institute (NCI)
National Institutes of Health (NIH)
Conditions:
Solid Tumor
Eligibility:
All Genders
18+ years
Brief Summary
RATIONALE: Studying samples of blood and urine in the laboratory from patients with cancer receiving epidermal growth factor receptor inhibitors may help doctors understand the effect of epidermal gro...
Detailed Description
OBJECTIVES: * Determine the effects of EGFR inhibitors on magnesium homeostasis in patients with cancer. OUTLINE: This is a pilot study. Patients undergo blood and urine sample collection at baseli...
Eligibility Criteria
Inclusion
- Diagnosis of malignancy
- Planning to receive therapy with an inhibitor of the EGFR pathway (either on or off a clinical trial and may be monotherapy or combined with other therapies)
- Normal serum magnesium level
Exclusion
- Glomerular filtration rate ≥ 60 mL/min
- No severe underlying renal dysfunction
- Normal serum potassium and calcium level
- No history of primary or secondary hyperparathyroidism
- PRIOR CONCURRENT THERAPY:
- No prior EGFR pathway inhibitor
Key Trial Info
Start Date :
May 1 2006
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 1 2009
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT00898027
Start Date
May 1 2006
End Date
February 1 2009
Last Update
January 29 2013
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.